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Abstract
Objective
Assessment of serum 25-hydroxyvitamin D (25(OH)D) correlations with clinical parameters
and evaluation of the efficacy of standard oral supplementation in systemic sclerosis (SSc)
patients.
Methods
154 SSc patients were recruited, in all seasons. Serum 25(OH)D concentrations were evalu-
ated using LIAISON 25-OH (Diasorin, Italy). Medsger disease severity scale (DSS), nailfold
videocapillaroscopy (NVC) and all instrumental exam contemplated by international guide-
lines were performed. Drug assumption, including oral colecalciferol, was evaluated. Non-
parametric tests were used for statistical analysis.
Results
Average 25(OH)D serum concentration was 18.7 ±9 ng/ml (<20 classified as deficiency). A
significant correlation was found with presence/absence of lung bi-basal fibrotic changes
(16.1 ±8 ng/ml and 20 ±10 ng/ml, respectively; p = 0.04). Peripheral vascular (p = 0.03), kid-
ney (p = 0.02), gastrointestinal (p = 0.05) Medsger’s DSS parameters were found to corre-
late with 25(OH)D serum concentrations. No significant correlations were observed with
digital ulcers incidence, strictly correlated to patterns of microangiopathy, defined at NVC
analysis (p<0.0001). Interestingly, no effects of treatment with oral colecalciferol (Dibase
1,000 IU daily for at least 6 months) were found on 25(OH)D serum concentrations in treated
(18.8 ±10 ng/ml) or untreated (18.7 ±9 ng/ml) SSc patients (p = 0.81). A significant differ-
ence was observed among seasonal 25(OH)D serum concentrations (winter: 14.6 ±7.8 ng/
ml, spring: 17.2 ±7.9 ng/ml, summer: 21.43 ±10 ng/ml, autumn: 20.2 ±10 ng/ml; p = 0.032) in
all patients.
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Conclusion
Serum 25(OH)D deficiency was found to correlate with lung involvement, peripheral vascu-
lar, kidney and gastrointestinal Medsger’s DSS parameters and with seasonality In SSc
patients. Supplementation with oral colecalciferol was found not effective in increasing 25
(OH)D serum concentrations. Therefore, for successful replacement, supra-physiological
vitamin D3 doses or programmed UVB light exposure should be tested.
Introduction
Systemic sclerosis (SSc) is a connective tissue disease of multifactorial etiology, mainly charac-
terized by microvascular damage followed by progressive fibrosis of skin and internal organs
[1]. In SSc patients, low 25-hydroxyvitamin D (25(OH)D) serum concentrations have been
shown and 25(OH)D deficiency was demonstrated to interfere with immune response [2, 3].
Vitamin D seems to play a key role both on innate and adaptive immune system and the
presence of its receptors on different cells types, seems to support this hypothesis. Especially in
systemic lupus erythematosus (SLE) and rheumatoid arthritis, a deficit in vitamin D serum
concentrations is evident and seems to correlate with disease course and outcome [4, 5].
Arnson et al. demonstrated, in a large multinational SSc patients’ population, that lower serum
vitamin D concentrations were inversely correlated with the extent of cutaneous fibrosis. However,
the effects of vitamin D supplements and seasonality of clinical assessments were not evaluated [6].
The purpose of the study was to correlate 25(OH)D serum concentrations, in a large cohort
of SSc patients from two European referral centers, with clinical complications and seasonality.
A further aim was to evaluate the efficacy of supplementation with oral colecalciferol in
increasing 25(OH)D serum concentrations.
Methods
A population of 154 consecutive SSc patients (diagnosis based on LeRoy 2001 and later con-
firmed by 2013 American College of Rheumatology (ACR)/European League Against Rheu-
matism (EULAR) criteria) was enrolled in the study [7, 8]). 91 patients were followed up at the
Rheumatology Division of Genoa University (Italy) and 63 at the Department of Rheumatol-
ogy of Ghent University Hospital (Belgium). As part of the regular follow up approved by both
Institutions for SSc, all patients undergone clinical evaluation and assessment of disease sever-
ity through the disease severity scale (DSS), developed by Medsger at al [9] (Fig 1). Serum con-
centration of 25(OH)D was evaluated by the direct competitive chemi-luminescence DiaSorin
LIAISON immunoassay (normal: 30–100 ng/ml). A concentration between 20 and 30 ng/ml
was classified as 25(OH)D insufficiency, while concentrations <20 ng/ml referred as defi-
ciency [10]. In all patients calcium concentrations were determined through COBAS, Roche
Diagnostics Ltd, (normal: 8.5–10.5 mg/dl). In 44 patients also PTH serum concentrations was
determined through DiaSorin LIAISON immunoassay (normal: 6.5–36 ng/l).
Patients assuming oral cholecalciferol (Dibase Abiogen Pharma, Italy), at the recommended
dose of 1,000 IU per day, for hypovitaminosis D prevention, were included in the study.
On the same date, nailfold videocapillaroscopy (NVC) was performed in all patients by the
same operator using an optical probe, equipped with a 200× contact lens, connected to an
image analysis software (Videocap, DS Medica, Milan, Italy). Nailfold capillaries abnormalities
were scored by a validated qualitative and semi-quantitative rating scale, in accordance with
previous studies [1, 11–13].
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Pulmonary function test with diffusing capacity of the lungs for carbon monoxide (DLCO),
chest x-ray, lung CT scan, electrocardiography (ECG), Doppler echocardiography with systolic
pulmonary arterial pressure (sPAP) measurement, renal artery resistive index (RI) by echo
color Doppler, were performed. Dual X-ray absorptiometry (DXA) was performed annually,
according to National Osteoporosis Foundation guidelines, to calculate trabecular bone score
(TBS) and bone mineral density (BMD) at the lumbar spine, hip, and proximal femur [14].
Drug assumption related effects were also evaluated (S1 File). All patients were informed that
their data would be used for possible studies/analyses and gave their consent when starting to
be followed up at the Clinic. Data were analyzed using IBM SPSS Statistics, Version 21.0. (IBM
Corp: Armonk, NY). Non-parametric tests were used for statistical analysis. A p value <0.05
was considered significant.
Results
Patients
Of the 154 patients enrolled, 131 were women and 21 men. Age was 59 ±15 years. Average
Raynaud’s phenomenon (RP) duration was 13.4 ±12.7 years, average disease duration was 6.5
±6.3 years (Table 1). Limited cutaneous (lcSSc) form frequency was 60%, diffuse cutaneous
form (dcSSc) frequency was 25%, and limited SSc (LSSc) form frequency was 15% (Table 1).
There was no statistically significant correlation between 25(OH)D serum concentrations
and sex (women 18.5 ±10 ng/ml, men 19.61 ±9 ng/ml; p = 0.63), age (p = 0.81), RP duration
(p = 0.69), disease duration (p = 0.43), dcSSc/lcSSc/LSSc involvement (dcSSc = 17 ±10 ng/ml,
lcSSc 17 ±8 ng/m, LSSc 20 ±10 ng/ml; p = 0.49).
Fig 1. Medsger’s disease severity scale (DSS) parameters in the study population. In the left part of the figure, a
graphic representation describes organ involvement through the distribution of the five values (0 to 4) for each parameter
of Medsger’s DSS (white = none, light grey = mild, intermediate grey = moderate, dark grey = severe, black = end-stage).
In the right part of the figure the same distribution is described in percentages (0 = none, 1 = mild, 2 = moderate,
3 = severe, 4 = end-stage).
https://doi.org/10.1371/journal.pone.0179062.g001
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Thirty-two percent of patients had digital ulcers (DUs) at the time of the investigation. No
correlation was reported between DUs incidence and 25(OH)D serum concentrations (no
DUs = 20.5 ±11 ng/ml, DUs = 15.5 ±10 ng/ml; p = 0.13), while DUs incidence correlated sig-
nificantly with patterns of microangiopathy (8% in “Early”, 33% in “Active”, 34% in “Late”
patients; p<0.0001). Morever, sub-classifying together “peripheral vascular” disease severity
scale parameter 0 to 1 (absence of digital trophic lesions) and 2 to 4 (presence of digital trophic
lesions), no significant difference was observed in 25(OH)D serum concentrations: 0–1
group = 18.3 ±9 ng/ml; 2–4 group = 17.1 ±9 ng/ml (p = 0.54). A highly significant correlation
with patterns of microangiopathy persisted in the last classification (digital trophic lesions 25%
in “Early”, 43% in “Active”, 63% in “Late” patients; p<0.0001).
Relevant treatment regimens are reported in Table 1.
Table 1. The table describes patients’ clinical characteristics, starting from personal data (age and gender), disease specific characteristics (dis-
ease subtype in percentages, autoantibody positivity in percentages, Raynaud’s phenomenon and disease durations, general digital ulcer inci-
dence and according to pattern of microangiopathy).
Patients clinical characteristics TOT 154
Age (years) 59 ±15
Gender (%) W = 131 (85)
M = 23 (15)
Disease subtype (%) dcSSc 25
lcSSc 60
LSSc 15
Autoantibody positivity (%) Anti-Scl 70 Ab 28.2
ACA Ab 56.4
Average RP duration (years) 13.4 ±12.7
Average disease duration (years) 6.5 ±6.3
DUs incidence (%) 32
By NVC pattern of micro-angiopathy “Early”: 8 (p<0.0001)
“Active”: 33
“Late”: 34
Average 25(OH)D (ng/ml) 18.7 ±9
Average 25(OH)D by region (ng/ml) Italy: 18 ±10 (p = 0.99)
Belgium: 19 ±9
Average 25(OH)D by season (ng/ml) Winter: 14.6 ±7.8 (p = 0.032)
Spring: 17.2 ±7.9
Summer: 21.43 ±10
Autumn: 20.2 ±10
Calcium (mg/dl) 9.3 ±0.4
PTH (44 patients) (ng/l) 28.6 ±14
Vit D supplementation 22
Treatments Glucocorticoids 18.1
(%) Calcium Channel blockers 22
Cyclic intravenous iloprost 61
PAH inhibitors 7.8
25(OH)D serum levels are reported as mean ± standard deviation and p value for all patients, according to patients region of origin and according to season
in which the patient has been evaluated). PTH serum levels are reported as mean ± standard deviation. Treatments regimens considered relevant were
reported as percentages of patients’ population. W = women; M = men; DcSSc = diffuse cutaneous systemic sclerosis; lcSSc = limited cutaneous systemic
sclerosis; LSSc = limited systemic sclerosis; Anti-Scl 70 Ab = anti–topoisomerase I antibody; ACA = anti-centromere antibody; RP = Raynaud’s
phenomenon; DUs = digital ulcers; NVC = Nailfold Videocapillaorscopy; PAH = pulmonary artery hypertension.
https://doi.org/10.1371/journal.pone.0179062.t001
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Laboratory and instrumental variables
Average 25(OH)D serum concentration in SSc patients was found 18.7 ±9 ng/ml (Table 1). Of
the 154 patients analyzed, 124 (80.5%) had 25(OH)D serum concentrations30 ng/ml, i.e.
classifiable as insufficiency, 87 (56.5%)20 ng/ml, defined as deficiency [11].
Anti-centromere antibodies (ACA-Ab) were detectable in 56.4%, Anti-Scl70 Ab in 28.2%
of SSc patients (Table 1). The average instrumental variables values are reported in Table 2.
No regional/latitude difference was observed between 25(OH)D serum concentrations in
the two groups: patients from Italy had an average of 18 ±10 ng/ml, patients from Belgium had
an average of 19 ±9 ng/ml (p = 0.99) (Table 1).
A significant difference was observed among seasonal vitamin D concentrations in the
population as a whole (p = 0.032). The Dunn’s multiple comparison post-test showed a more
significant difference between patients observed in winter compared to summer months
(p = 0.0086) (Table 1 and Fig 2A).
Average calcium concentrations were determined in all patients: 9.3 ±0.4 mg/dl. In 44
patients also PTH serum concentrations were determined: 28.6 ±14 ng/l (Table 1). A tendency
to direct correlation was observed between 25(OH)D and calcium serum concentrations
(p = 0.050, Spearman r = 0.18) while a non significant tendency to inverse correlations was
observed between 25(OH)D and PTH serum concentrations (p = 0.07, Spearman r = -0.27).
Interestingly, a statistically significant correlation was found between 25(OH)D serum con-
centrations and presence/absence of bi-basal fibrotic changes at lung CT scan (average: 16.1
±8 ng/ml and 20 ±10 ng/ml, respectively, p = 0.04) (Fig 2B).
No correlation was found between 25(OH)D serum concentrations and autoantibody spec-
ificity (anti-centromere Ab = 18.5 ±10 ng/ml, Scl-70 Ab 18.9 ±9 ng/ml; p = 0.84), videocapil-
laroscopic pattern (“Early” = 23.3 ±11 ng/ml, “Active” = 18.7 ±9 ng/ml, “Late” = 17.7 ±9 ng/
ml; p = 0.2), haemoglobine (Hb) (p = 0.9), erythrocyte sedimentation rate (ESR) (p = 0.37),
C-reactive protein (CRP) (p = 0.67), creatinine (p = 0.11), interstitial lung disease at CT scan
Table 2. The table describes organ involvement in patients population as assessed through laboratory (creatinine levels) and instrumental param-
eters: Average pulmonary function test measurements (DLCO%, FVC% and FVC%/DLCO% ratio), average echocardiographic estimation of SPAP
values, patients percentage showing interstitial lung disease or bi-basal fibrotic changes at lung CT scan, patients percentage showing enlarged
hearth at chest X-rays, patients percentage showing ECG alterations (conduction disorders and arrhythmias), patients percentage for each nail-
fold videocapillaroscopic pattern.
Laboratory and instrumental parameters TOT 154
Blood tests Creatinine levels (mg/dl) 1.01 ±0.4
Pulmonary DLCO % (mean ±SD) 75 ±18
function FVC% (mean ±SD) 104 ±21
test FVC%/DLCO% (mean ±SD) 1.4 ±0.4
Echocardiography sPAP (mean ±SD) 31.6 ±7
CT Scan Interstitial lung disease (%) 46
Bi-basal fibrotic changes (%) 44
Chest X-rays Enlarged heart (%) 12
Electrocardiography Conduction disorder (%) 19
Arrythmias (%) 5
NVC Patterns (%) Early 15.6
Active 34.3
Late 50
DLCO = diffusing capacity of the lungs for carbon monoxide; SD = standard deviation; FVC = forced vital capacity, sPAP = systolic pulmonary arterial
pressure, NVC = Nailfold Videocapillaroscopy.
https://doi.org/10.1371/journal.pone.0179062.t002
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(presence = 18 ±9 ng/ml, absence = 18 ±11 ng/ml, p = 0.82), total lung capacity (p = 0.23),
forced vital capacity (p = 0.7), forced expiratory volume in the 1st second (p = 0.5), DLCO%
(p = 0.3), sPAP (p = 0.79) enlarged hearth size at chest x-ray (presence = 18.3 ±10 ng/ml,
absence = 18.4 ±10 ng/ml, p = 0.84), conduction disorders at ECG (presence = 20 ±8 ng/ml,
absence = 19 ±10 ng/ml, p = 0.3).
No correlations were observed between 25(OH)D serum concentrations and trabecular
bone score (TBS) (p = 0.85), BMD, T-scores and Z-scores. Moreover, no correlation was
observed among DXA scan data and glucocorticoid therapy (Table 3).
Interestingly, an ongoing pilot study shows no correlation between 25(OH)D serum con-
centration and peripheral blood flow in SSc patients as analyzed by laser speckled contrast
analysis (LASCA) or skin thickness, evaluated by skin echography on a small proportion of the
same SSc patients (23/154) (data not shown).
25-hydroxyvitamin D serum concentrations and Medsger’s disease
severity scale parameters
Medsger’s disease severity scale values are reported in Fig 1. DSS parameters that significantly
correlated with 25(OH)D serum concentration were: “peripheral vascular” (0 = 21 ±8 ng/ml,
1 = 17.7 ±9 ng/ml, 2 = 18.7 ±9 ng/ml, 3 = 14.99 ±9 ng/ml, 4 = 4.7 ±0.4 ng/ml; p = 0.03), “kid-
neys” (0 = 17.5 ± 8 ng/ml, 1 = 26.8 ± 15 ng/ml, 2 = 21 ± 10 ng/ml, 3 = 4.2 ± 0.2 ng/ml;
p = 0.02), “gastrointestinal” (0 = 19.53 ± 9 ng/ml, 1 = 16.01 ± 9 ng/ml, 2 = 14.00± 12 ng/ml;
p = 0.05) (Figs 1, 2C, 2D and 2E).
Fig 2. 25(OH)D serum levels and significant correlations. A) Average 25(OH)D serum concentrations in all
seasons: a statistically significant difference was observed among seasonal 25(OH)D serum concentrations
(p = 0.032). The Dunn’s multiple comparison post-test shows a more significant difference between patients
observed in winter compared to summer months (p = 0.0086). B) Average 25(OH)D serum concentrations in
patients showing presence/absence of bi-basal fibrotic changes at lung CT scan: a statistically significant
difference was found between 25(OH)D serum concentrations in patients showing presence vs absence of bi-
basal fibrotic changes at lung CT scan (p = 0.04). C) Medsger’s disease severity scale “peripheral vascular”
parameter correlation with 25(OH)D serum concentrations (p = 0.03).D) Medsger’s disease severity scale
“kidney” parameter correlation with 25(OH)D serum concentrations (p = 0.02). E) Medsger’s disease severity
scale “gastro-intestinal” parameter correlation with 25(OH)D serum concentrations (p = 0.05).
https://doi.org/10.1371/journal.pone.0179062.g002
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DSS parameters that did not correlate with 25(OH)D serum concentrations were: “general
health” (0 = 8.2 ±9 ng/ml, 1 = 18.41 ±8 ng/ml, 2 = 16.35±14 ng/ml; 0.8), “skin” (0 = 19.8 ±8 ng/
ml, 1 = 19.2 ±10 ng/ml, 2 = 17.1 ±9 ng/ml, 3 = 15.3 ±9 ng/ml; p = 0.36), “hearth” (0 = 18.11
±10 ng/ml, 1 = 19.27 ± 8 ng/ml, 2 = 22.85 ±14 ng/ml, 3 = 19.35 ±9 ng/ml; p = 0.77), “lung”
(0 = 17.05 ±8 ng/ml, 1 = 19.9 ±10 ng/ml, 2 = 16.00 ±9 ng/ml, 3 = 18.60 ±8 ng/ml; p = 0.34),
“muscle” (0 = 18.1 ±9 ng/ml, 1 = 16.5 ±8 ng/ml, 2 = 18.3 ±9 ng/ml; p = 0.93), “joint/tendon”
Table 3. In the left part of the table DXA scan parameters average values in all patients population are shown. In the right part of the table there are p
values for correlation of DXA scan data with 25(OH)D serum levels and with glucocorticoid therapy.
DXA Scan Data Mean ± SD Correlation with Correlation with
serum 25(OH)D glucocorticoid therapy
(p values) (p values)
L1-L4 BMD 0.9 ±0.17 0.36 0.14
T SCORE -1.5 ±1.4 0.83 0.13
Z SCORE 0.2 ±1.2 0.87 0.36
Neck BMD 0.7 ±0.1 0.38 0.98
T SCORE -2 ±0.9 0.43 0.47
Z SCORE -0.5 ±0.8 0.19 0.6
Ward BMD 0.5 ±0.1 0.38 0.46
T SCORE -2.7 ±0.8 0.83 0.44
Z SCORE -0.7 ±0.7 0.41 0.7
Trochanteric BMD 0.6 ±0.1 0.39 0.33
T SCORE -1.1 ±0.9 0.51 0.16
Z SCORE -0.3 ±0.8 0.50 0.18
Whole BMD 0.8 ±0.1 0.48 0.24
T SCORE -1.6 ±0.9 0.56 0.14
Z SCORE -0.3 ±0.8 0.41 0.21
No correlations were observed between 25(OH)D serum concentration and bone mineral density (BMD) at the lumbar spine (L1-L4), hip, and proximal
femur. No correlations were observed among dual X-ray absorptiometry (DXA) scan data and glucocorticoid therapy assumption.
https://doi.org/10.1371/journal.pone.0179062.t003
Fig 3. 25(OH)D serum concentrations and treatment. 25(OH)D serum concentrations compared in
patients assuming/not assuming supplementation with 1,000 IU daily for at least 6–12 months. There was no
influence of treatments with oral colecalciferol on 25(OH)D serum concentrations: 18.8 ±10 ng/ml in treated
and 18.7 ±9 ng/ml in untreated patients (p = 0.81).
https://doi.org/10.1371/journal.pone.0179062.g003
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(0 = 18.18 ±9 ng/ml, 1 = 14.90 ±6 ng/ml, 2 = 17.75 ±9 ng/ml, 3 = 35 ±10 ng/ml, 4 = 18 ±15 ng/
ml; p = 0.57).
25-hydroxyvitamin D serum concentration and treatments
Relevant treatment regimens are reported in Table 1. Interestingly, there was no influence of
treatments with oral colecalciferol (1,000 IU daily for 6–12 months) on 25(OH)D serum con-
centrations: 18.8 ±10 ng/ml in treated and 18.7 ±9 ng/ml in untreated patients (p = 0.81) (Fig
3).
No difference in 25(OH)D serum concentrations were observed in patients assuming/not
assuming glucocorticoids (21 ±12 ng/ml VS 17.8 ±9 ng/ml respectively; p = 0.36), cyclic intra-
venous iloprost (19 ±9 ng/ml VS 18 ± 10 ng/ml; p = 0.43), calcium channel blockers (22 ±11
ng/ml VS 17.9 ±9 ng/ml respectively; p = 0.09), pulmonary arterial hypertension (ERAs) treat-
ment (19 ± 10 ng/ml VS 18 ±10 ng/ml, p = 0.5) (Table 1).
Discussion
Serum 25(OH)D deficiency was found in more than 50% of SSc patients and significant fluctu-
ations according to seasons were confirmed in almost all patients. In addition, for the first
time to our knowledge, deficent/insufficient 25(OH)D serum concentrations were found to be
independent from standard oral supplementation.
As a matter of fact, 25(OH)D serum concentrations were below 30 ng/ml in more then 80%
of the SSc patients. This reported cut-off level for “sufficiency” was established because intesti-
nal calcium absorption is optimized at a concentration above 30–32 ng/ml and parathyroid
hormone start to rise when 25(OH)D is below 31 ng/ml [15].
As expected, calcium levels correlated almost significantly with 25(OH)D serum concentra-
tions, conversely we found a non significant increase in PTH levels, but probably these data
are affected by the smaller number of patients examined.
The variability of 25(OH)D serum concentrations was demonstrated to have a strong
genetic component [16]. A good example is SLE, in which serum 25(OH)D serum concentra-
tions were associated with vitamin D receptor (VDR) polymorphisms [17].
A recent study showed that low serum concentrations of 25(OH)D has negative impact in
diffuse SSc patients’ quality of life and in addition, a correlation with severe NVC alterations
was reported, suggesting a possible role of 25(OH)D in vascular involvement [18]. Further-
more, recently a significant difference in serum IgM anti-vitamin D antibodies in SSc patients
was found, compared to healthy controls [19]. Other Authors did not find correlations
between a more severe disease and 25(OH)D serum concentrations [20].
We have shown in the present large study from two European referral centers, that low 25
(OH)D serum concentrations are associated, in SSc patients, with bilateral fibrosis at lung CT
scan and to Medsger’s DSS parameters “peripheral vascular”, “kidney” and “gastrointestinal”.
A severe lung involvement was already described in SSc patients with low 25(OH)D serum
concentrations [21]. In the present study however, we do not observe a linear correlation
between 25(OH)D concentration and DLCO values, but only a more severe 25(OH)D defi-
ciency was observed in patients with bilateral pulmonary fibrosis on lung CT scan compared
to those with milder/no lung involvement. Therefore, in this case hypovitaminosis D seems to
be associated only to severe pulmonary structural damage.
The scarce significance of data on gut and lung involvement is probably due to the pro-
nounced 25(OH)D deficiency in all patients. Furthermore, this particular population did not
show a great differentiation in terms of gastrointestinal involvement according to Medsger’s
DSS, having very few patients in classes 3 and 4.
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Regarding Medsger’s DSS “peripheral vascular” parameter, this is based on both severity of
Raynaud’s phenomenon and presence of digital lesions (0 = normal, 1 = Raynaud’s requiring
vasodilators, 2 = digital pitting scars, 3 = digital tip ulcerations, 4 = digital gangrene) [9]. In the
study population, DUs incidence (stage 3 of “peripheral vascular parameter”) taken singularly
or presence of any digital trophic lesion (stage 2 to 4 of “peripheral vascular parameter”),
appeared to correlate strongly with NVC patterns of microangiopathy and not with 25(OH)D
serum concentrations. Our data confirm literature reports affirming that patients with “Late”
NVC pattern are more prone to development of trophic digital lesions [1]. Probably for this
parameter, only degrees 0 and 1 of Medsger’s DSS are more related to functional/milder alter-
ations of the vascular system, mostly influencing the lack of vitamin D efficient metabolism.
Organ involvement and disease severity relation with vitamin D, could be explained by its
immune-regolatory properties. In fact, impairment of self-tolerance and immune responses,
through altered regulation of dendritic cells, regulatory T-lymphocytes (Tregs), Th1 cells and
B cells functions were described in hypovitaminosis D [22]. Even in healthy controls, antinu-
clear antibodies (ANA)-positivity was associated with lower vitamin D serum concentration in
comparison with ANA negative individuals [23].
Previous studies demonstrated that, in rheumatoid arthritis synovial tissue, 1,25-dihydroxy-
vitamin D3 may downregulate pro-inflammatory cytokine production in activated macro-
phages, decreasing aromatase activity, especially in presence of an estrogenic milieu [24]. A
study from our group showed, for the first time, in 53 SSc patients and 35 healthy controls, the
significant seasonal changes of 25(OH)D serum concentrations, with peak values in late sum-
mer and decreased values in late winter [25].
An important finding of this study is that a seasonal variation in 25(OH)D serum concen-
tration is confirmed. The result would suggest that vitamin D synthesis phases held in the skin
are at least partially preserved. This concept might have an interest for the development of
therapeutic strategies for hypovitaminosis D in SSc patients.
Ultraviolet B rays (UVB) cause the non-enzymatic conversion of 7-dehydrocholesterol to
pre-vitamin D3 In the skin. In the liver, pre-vitamin D3 is converted in 25(OH)D3 and then to
the active form 1,25-dihydroxivitamin D3 in the kidney. For this reason, the first step for ade-
quate vitamin D supply to the human body is through adequate skin synthesis.
It is possible that in SSc patients with severe organ involvement, sunlight exposure could be
reduced for different reasons (sedentary attitude, reduced mobility, hospitalization) contribut-
ing to the high prevalence of vitamin D deficiency/insufficiency. Moreover, the higher skin
pigmentation described in SSc patients is a factor to be considered, especially in those affected
by diffuse form [26]. In fact, cutaneous pre-vitamin D production was described to be related
to melanin amount in the skin, being melanin a good absorbent of UVB rays [27]. Higher skin
pigmentation was demonstrated to worsen vitamin D deficiency, as well as malabsorption and
small intestine function is known to be frequently altered in SSc patients [28–31].
However, independently from severity of the disease, some patients with malabsorption
have a normal concentration of serum vitamin D, while healthy subjects can show hypovitami-
nosis [32]. A common factor in SSc, Crohn’s disease and ulcerative colitis that may be a con-
tributory cause for vitamin D deficit is intestinal inflammation [33]. Fecal calprotectin is a
common marker of gut involvement in all conditions cited and was shown to correlate inde-
pendently with low vitamin D serum concentration in SSc patients [34]. Furthermore, gut is
one of the extra-renal sites were inflammation drives the hyper-expression of CYP24A1 and
CYP27B1, therefore, reducing 25(OH)D through induction of a higher rate of conversion to
1,25(OH)2D.
Reduced absorption capacity of small intestine was postulated to be determinant for failure
of oral treatment with physiological/standard doses of oral colecalciferol [35].
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Vitamin D3 (colecalciferol, Dibase Abiogen Pharma, Italy) 1,000 IU/die was used in our
patients for oral supplementation, being its effectiveness already demonstrated in comparison
with vitamin D2 [36]. In a 2014 Cochrane Review, the Authors concluded that vitamin D3
seemed to decrease mortality in elderly people living independently or in institutional care
while vitamin D2, alfacalcidol and calcitriol had no statistically significant beneficial effects on
mortality [37]. Interestingly, in our patients population, the oral substitutive treatment with
oral colecalciferol (time range 6–12 months) was not influencing 25(OH)D serum concentra-
tion, while an evident influence was exerted by seasons, with patients observed in winter
months having a significantly more severe hypovitaminosis D, compared to those observed in
summer months. The result seems coherent with reports on vitamin D deficiency secondary to
diseases characterized by malabsorption [38, 39]. However, some authors postulate the possi-
bility of achieving better results in selected patients using vitamin supra-physiological vitamin
D doses: up to 5,000 IU daily for 24 weeks for three-six months in Chron’s disease, 50,000 IU
bi-weekly for 12 weeks in cystic fibrosis were used [40, 41].
Sensible sun exposure, especially between the hours of 10:00 am and 3:00 pm seems to pro-
duce serum 25(OH)D in the skin lasting twice as long compared with vitamin D assumed
orally. However, as mentioned, a variety of factors reduce the skin production, including
increased skin pigmentation, aging, and topical application of a sunscreen [42].
A clinical study from Sweden showed UVB therapy to be more efficacious in raising serum
25(OH)D concentrations in deficient subjects. This suggests that UVB therapy may be a useful
therapeutic approach in selected individuals [43].
It has to be mentioned that new in vivo pathways of D3 metabolism regulated by P450 and
CYP11A1 cytochromes were described, in recent years, in animals and humans steroidogenic
tissues. Products of the aforementioned metabolisms are D3 hydroxyderivatives (main metab-
olite 20(OH)D3) with activities that are similar to 25(OH)D3 and 1,25(OH)2D3 [44–46].
The Authors demonstrated that human dermal fibroblasts can transform D3 to 20(OH)D3,
22(OH)D3, 20,22(OH)2D3, 20,23(OH)2D3 and 1,20(OH)2D3 [47]. Therefore, P450 and
CYP11A1-derived secosteroids might be studied, in the future, in diseases involving the skin,
for their pathogenic and therapeutic potentials.
This study had several limitations. We did not have a control group but we compared 25
(OH)D serum concentration with average healthy population values. However it as to be said
that it was not among the purposes of this study to demonstrate a difference in 25(OH)D
serum concentrations between SSc patients and healthy subjects, being this topic already
addressed by other Authors [2, 3]. We mainly wanted to investigate on the possible existing
relations between 25(OH)D serum concentrations, clinical complications, seasonality and sup-
plementation with oral colecalciferol.
In addition, we did not evaluate PTH serum concentrations in all patients and in no patient
serum concentration of 1,25(OH)2D were performed. However, the 25(OH)D deficit has been
reported to be due to higher conversion rate of 25(OH)D to 1,25(OH)2D upon extra-renal
hyperactivity of the CYP27B1 in inflamed tissues [48].
Since this was a retrospective data analysis, we have not had the opportunity to perform
other tests to assess the severity of a possible malabsorption (iron or other vitamins deficiency,
elettrolites alterations, hypo-proteinemia, hypo-lipemia, stool examination alterations).
Finally, precise quantitative reports of sunlight exposure and cutaneous hyperpigmentation
in patients were not reported.
In conclusion, a serum 25(OH)D deficiency in SSc is confirmed. The last seems to be worse
in cold seasons and to correlate with severe lung involvement at CT scan, as well as with
“peripheral vascular”, “kidney” and “gastrointestinal” damage (Medsger’s DSS). Low 25(OH)
D serum concentrations failed to be corrected by oral colecalciferol administration. Therefore,
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we suggest to monitor 25(OH)D serum concentrations after 3–6 months from the start of
treatment. In case of persistently low 25(OH)D serum concentrations, supra-physiological oral
vitamin D doses or programmed UVB light exposure should be considered [49, 50].
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